Rathbones Group PLC Invests $473,000 in SPDR S&P Biotech ETF $XBI

Rathbones Group PLC bought a new position in SPDR S&P Biotech ETF (NYSEARCA:XBI) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 3,883 shares of the exchange traded fund’s stock, valued at approximately $473,000.

Several other large investors have also made changes to their positions in XBI. Capital A Wealth Management LLC bought a new stake in shares of SPDR S&P Biotech ETF in the 2nd quarter worth about $26,000. Davis Capital Management bought a new stake in SPDR S&P Biotech ETF during the 3rd quarter worth about $35,000. Halbert Hargrove Global Advisors LLC bought a new stake in SPDR S&P Biotech ETF during the 3rd quarter worth about $40,000. Barnes Dennig Private Wealth Management LLC bought a new stake in SPDR S&P Biotech ETF during the 4th quarter worth about $48,000. Finally, Premier Financial Group bought a new stake in SPDR S&P Biotech ETF during the 3rd quarter worth about $50,000.

SPDR S&P Biotech ETF Stock Up 1.4%

Shares of NYSEARCA:XBI opened at $130.65 on Thursday. SPDR S&P Biotech ETF has a 12 month low of $66.66 and a 12 month high of $133.27. The company’s 50-day moving average price is $125.11 and its two-hundred day moving average price is $119.10. The firm has a market cap of $7.96 billion, a P/E ratio of 11.47 and a beta of 0.91.

About SPDR S&P Biotech ETF

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.